KRW104,950.00
4.64% today
Korea, Sep 03, 08:11 am CET
ISIN
KR7326030004
Symbol
326030
Index

SK Biopharmaceuticals Stock price

KRW105,000.00
+8,900.00 9.26% 1M
-9,000.00 7.89% 6M
-6,100.00 5.49% YTD
-5,500.00 4.98% 1Y
+35,700.00 51.52% 3Y
-77,000.00 42.31% 5Y
-22,000.00 17.32% 10Y
-22,000.00 17.32% 20Y
Korea, Closing price Wed, Sep 03 2025
+4,700.00 4.69%
ISIN
KR7326030004
Symbol
326030
Index
Industry

Key metrics

Basic
Market capitalization
KRW7.7t
Enterprise Value
KRW7.5t
Net debt
positive
Cash
KRW222.6b
Shares outstanding
78.3m
Valuation (TTM | estimate)
P/E
30.7 | 61.0
P/S
12.4 | 10.9
EV/Sales
12.1 | 10.7
EV/FCF
84.7
P/B
12.9
Financial Health
Equity Ratio
52.7%
Return on Equity
44.1%
ROCE
21.4%
ROIC
66.3%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
KRW620.3b | KRW702.1b
EBITDA
KRW164.1b | KRW193.6b
EBIT
KRW147.6b | KRW158.1b
Net Income
KRW256.0b | KRW128.8b
Free Cash Flow
KRW88.8b
Growth (TTM | estimate)
Revenue
33.4% | 28.2%
EBITDA
185.2% | 70.2%
EBIT
265.1% | 64.2%
Net Income
657.5% | -46.5%
Free Cash Flow
1,087.9%
Margin (TTM | estimate)
Gross
93.1%
EBITDA
26.5% | 27.6%
EBIT
23.8%
Net
41.3% | 18.3%
Free Cash Flow
14.3%
More
EPS
KRW3,268.8
FCF per Share
KRW1,134.2
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is SK Biopharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

SK Biopharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a SK Biopharmaceuticals forecast:

20x Buy
80%
4x Hold
16%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a SK Biopharmaceuticals forecast:

Buy
80%
Hold
16%
Sell
4%

Financial data from SK Biopharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
620,280 620,280
33% 33%
100%
- Direct Costs 42,813 42,813
3% 3%
7%
577,467 577,467
36% 36%
93%
- Selling and Administrative Expenses 253,231 253,231
18% 18%
41%
- Research and Development Expense 160,104 160,104
5% 5%
26%
164,132 164,132
185% 185%
26%
- Depreciation and Amortization 16,579 16,579
3% 3%
3%
EBIT (Operating Income) EBIT 147,553 147,553
265% 265%
24%
Net Profit 255,991 255,991
657% 657%
41%

In millions KRW.

Don't miss a Thing! We will send you all news about SK Biopharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

SK Biopharmaceuticals Co., Ltd. engages in the research and development of new drugs and antibiotics. It mainly develops new drugs for central nervous system disorders, and brain tumors. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea.

Head office South Korea
CEO Dong-Hoon Lee
Founded 1993
Website www.skbp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today